Insurance Financial Performance Analysis Of JL Pharmaceuti Industry's Backdoor Listing

In recent years,China's economy is in a transitional period,coupled with the entry of international capital,the market competition is becoming increasingly fierce,forcing more and more enterprises to expand their market size by listing.Merger and acquisition reorganization is usually a means of resource integration used by enterprises to improve their business conditions by virtue of superior resources.As a new way of merger and acquisition reorganization,shell-back reorganization has developed rapidly in recent years.Due to the shortcomings of long audit time and high standards in IPO listing,backdoor listing has become a preferred listing method for enterprises.Through backdoor listing,enterprises can achieve rapid integration of effective resources,use the financing obtained to invest in product research and development,and ensure the sustainable and healthy development of enterprises by improving the quality of products.While backdoor listing brings many conveniences,there are also many problems:whether the two enterprises can effectively merge after backdoor listing,whether shell resources can not bring financing on schedule,and low profits due to the cost of trading schemes.Even after the successful listing of some enterprises,there are also problems such as poor performance,poor financing effect,which lead to the rupture of the capital chain.Therefore,through this study,we hope to avoid the above risks.Firstly,this paper defines the related concepts of backdoor listing,systematically expounds the relevant basic theory of backdoor listing,and comprehensively analyses the current situation of mergers and acquisitions of pharmaceutical industry,the operation status of the two companies before restructuring,the motivation of backdoor listing of JL pharmaceutical industry and the operation process of backdoor listing.On this basis,it analyses the backdoor listing from the short-term perspective,the long-term perspective and the EVA evaluation system respectively.The changes brought by backdoor listing to JL Pharmaceutical Industry and the reasons for the changes.Through case studies,it is found that backdoor listing will enhance the confidence of the market in the development of the company.Listing will expand the scope of business,but at the same time,it will also increase the risk of business operation and overall improve the company performance of JL Pharmaceutical.Based on the above conclusions,this paper gives the corresponding countermeasures and suggestions for the companies that will adopt backdoor listing,in order to provide some reference for enterprise practice.